Equibles does not estimate personal net worth.
Get an email with a short summary when Ocular Therapeutix, Inc publishes a filing, an earnings call transcript or a press release.
Get OCUL alertsPravin Dugel is recorded as Chairman and CEO at Ocular Therapeutix, Inc (OCUL). Pravin Dugel has spoken on 5 earnings calls across 1 company, most recently for Ocular Therapeutix, Inc on May 5, 2026. Ocular Therapeutix, Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ocular Therapeutix, Inc includes Pravin U. Dugel (CEO, Chairman and Board Member), Pravin U. Dugel, M.D. (CEO and Chairman), Charles Warden (Chairman and Board Member) and 7 others.
“2026 is off to a tremendous start for ocular therapeutics. And I want to begin by stating this clearly. SOL1 has fundamentally changed the conversation in wet AMD.”
“At Ocular Therapeutix, we are courageous, bold, and opportunistic. We make decisions from a position of confidence. We refuse to accept the status quo in drug development, trial design, and our approach to the retina market.”
“2025 is shaping up to be a defining year for Ocular Therapeutix. As we look back on the progress made over the first half of the year, I'm proud to say we are continuing to execute with precision, speed and scientific integrity.”
“2024 was a transformational year for Ocular Therapeutix. We sharpened our focus and embraced a single, bold mission: to redefine the retina experience.”
“When I joined Ocular, our number one priority was bringing AXPAXLI to market for wet age-related macular degeneration. Wet AMD affects about 1.65 million people in the United States, which translates to approximately one in every 160 adults.”
Biotechnology · Healthcare
Chairman, CEO
